Precisio announced a first-in-man dosing of its staph lysin called ClyO (LYSG101) to a patient with a prosthetic joint infection that had not responded to other treatments. The FDA approved this ...

Precisio announced a first-in-man dosing of its staph lysin called ClyO (LYSG101) to a patient with a prosthetic joint infection that had not responded to other treatments. The FDA approved this ...

DOVER, Del.-- (BUSINESS WIRE)-- Precisio announced a first-in-man dosing of its staph lysin called ClyO (LYSG101) to a patient with a prosthetic joint infection that had not responded to other ...